Shouman Wang
Overview
Explore the profile of Shouman Wang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
364
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen L, Li H, Zhang H, Yang H, Qian J, Li Z, et al.
JAMA
. 2024 Dec;
333(8):673-681.
PMID: 39671272
Importance: Preferred neoadjuvant strategies for early or locally advanced triple-negative breast cancer include a 4-drug chemotherapy regimen containing anthracyclines, cyclophosphamide, taxanes, and platinum. Blockade of the programmed death receptor 1/ligand-1...
2.
Pang J, Ding N, Liu X, He X, Zhou W, Xie H, et al.
Ann Surg Oncol
. 2024 Dec;
32(3):2110-2111.
PMID: 39656393
No abstract available.
3.
Pang J, Ding N, Liu X, He X, Zhou W, Xie H, et al.
Ann Surg Oncol
. 2024 Nov;
32(2):750-759.
PMID: 39565489
Purpose: The systemic immune-inflammation index (SII) is a hematological marker that reflects the immune status of the body. This study was designed to evaluate the prognostic significance of the baseline...
4.
Hong Y, Peng J, Chen Q, Zhou Q, Xu F, Yao J, et al.
Ther Adv Med Oncol
. 2024 Sep;
16:17588359241279695.
PMID: 39346118
Background: Pegylated liposomal doxorubicin (PLD), epirubicin and pirarubicin are the main anthracyclines widely used in China. PLD demonstrates therapeutic response comparable to epirubicin and pirarubicin in neoadjuvant chemotherapy (NAC) of...
5.
Zeng F, Heng J, Guo X, Wang Y, Wu W, Tang L, et al.
Breast Cancer Res Treat
. 2024 Aug;
208(2):469.
PMID: 39115724
No abstract available.
6.
Yao H, Yan M, Tong Z, Wu X, Ryu M, Park J, et al.
J Clin Oncol
. 2024 Jun;
42(29):3453-3465.
PMID: 38900984
Purpose: SHR-A1811 is an antibody-drug conjugate composed of an anti-human epidermal growth factor receptor 2 (HER2) antibody trastuzumab, a cleavable linker, and a topoisomerase I inhibitor payload. We assessed the...
7.
Peng J, Hong Y, Chen Q, Xu F, Zhang D, Yao J, et al.
Front Endocrinol (Lausanne)
. 2024 Apr;
15:1347762.
PMID: 38567311
Objective: Hormone receptor (HR)-low/HER2-negative breast cancers (BCs) are more likely to be basal-like BCs, with similar molecular features and gene expression profiles to HR-negative (estrogen receptor <1% or negative and...
8.
Xie Q, Liu S, Zhang S, Liao L, Xiao Z, Wang S, et al.
Clin Exp Med
. 2024 Mar;
24(1):49.
PMID: 38427120
In the dynamic process of metastasis, circulating tumor cells (CTCs) emanate from the primary solid tumor and subsequently acquire the capacity to disengage from the basement membrane, facilitating their infiltration...
9.
Ding N, Pang J, Liu X, He X, Zhou W, Xie H, et al.
Breast Cancer Res
. 2024 Jan;
26(1):9.
PMID: 38212845
Purpose: This study aimed to evaluate the prognostic role of the baseline neutrophil/lymphocyte ratio (NLR) in HER2-positive metastatic breast cancer (MBC) patients treated with trastuzumab/pertuzumab. Experimental Design: Data from 780...
10.
Zhou Z, Cao Y, Yang Y, Wang S, Chen F
Epigenetics
. 2023 May;
18(1):2217033.
PMID: 37243702
Doxorubicin (DOX) resistance in breast cancer (BC) poses a huge challenge for the therapeutic effect on BC. Lnc KCNQ1OT1 play crucial roles in chemotherapy resistance. However, the role and mechanism...